

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients

Etienne De Clara,¹ Morgane Gourvest,¹ Hanjing Ma,² François Vergez,^{1,3} Marie Tosolini,¹ Sébastien Dejean,⁴ Cécile Demur,^{1,3} Eric Delabesse,^{1,3} Christian Recher,^{1,3} Christian Touriol,¹ Maria Paola Martelli,⁵ Brunangelo Falini,⁵ Pierre Brousset^{1,6} and Marina Bousquet¹

EDC, MG and HM contributed equally to this work.

¹Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm/Université Toulouse III Paul Sabatier, ERL5294 CNRS, Laboratoire d'Excellence Toulouse Cancer (TOUCAN), France; ²BGI, Shenzhen, China; ³Laboratoire et Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer, France; ⁴Institut de Mathématiques de Toulouse, UMR 5219 Université de Toulouse/CNRS Université Paul Sabatier, France; ⁵Institute of Hematology, University of Perugia, Ospedale S. Maria della Misericordia, Italy and ⁶Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole and Centre Hospitalier Universitaire de Toulouse, France

©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.171645

Received: April 25, 2017.

Accepted: June 22, 2017.

Pre-published: July 04, 2017.

Correspondence: bousquetmarina@gmail.com

SUPPLEMENTARY DATA

SUPPLEMENTARY METHODS

AML samples

Cohort 1 was composed of forty CN-AML samples collected from patients registered at the HIMIP (Hémopathies INSERM Midi-Pyrénées) collection. For the validation cohort (Cohort 2, n=134), thirty-four CN-AML samples were obtained from the HIMIP collection, 7 CN-AML samples from the Hematology Institute of Perugia University and 93 CN-AML samples from the FILOtheque AML, Paris. Fresh and thawed samples were obtained after informed consent and the study was conducted in accordance with the Declaration of Helsinki and was approved by a local ethics committee.

Seventy-four AML samples (40 samples for Cohort 1 and 34 samples for Cohort 2) were collected from patients registered at the HIMIP. In accordance with French law, the HIMIP collection has been declared to the Ministry of Higher Education and Research (DC 2008-307 collection 1) and a transfer agreement has been obtained (AC 2008-129) after approbation by local ethical committees (the Comité de Protection des Personnes Sud-Ouest et Outremer II and the APHP ethical committee). Clinical and biological annotations have also been declared to the CNIL (Comité National Informatique et Libertés).

Seven AML samples were obtained from the Hematology Institute of Perugia University. These patients had received standard induction regimens (i.e. an anthracycline and cytarabine “3+7” combination). Patients who had achieved complete remission received one or two cycles of consolidation therapy and/or allogeneic stem cell transplantation.

Ninety-three AML samples (included in Cohort 2) were collected from patients registered at the FILOtheque. The handling, conditioning and storing of patient samples was performed by the FILOtheque AML (N° BB-0033-00073) tumor bank of the FILO group, Cochin Hospital, Paris. Fifty-four patients were enrolled in the AML 2006 IR trial and thirty-nine

patients in the AML 2007 SA trial. AML 2006 IR was a multicenter, randomized, open-label, phase III trial assessing the efficacy of gemtuzumab ozogamycin (GO, or MYLOTARG) in association with intensive chemotherapy in intermediate risk AML patients aged 18 to 60 years, in which patients received standard daunorubicin/cytarabine induction therapy with or without GO at a dose of 6 mg/m² on day 4. AML 2007 SA was a multicenter randomized trial comparing induction therapy with IC (idarubicin and cytarabine, “5+7”) to ICL (the same drugs plus lomustine (CCNU), 200 mg/m² administered orally at day 1) in patients older than 60 years. Patients in complete remission (CR) received a post-remission schedule with or without lomustine, according to randomization.

For prognosis analysis, we discarded patients that had not received intensive chemotherapy, who were older than 75 years old and for whom no clinical information was available.

RNA isolation and cDNA synthesis

Total RNAs were extracted with the TRIzol reagent (Ambion, Austin, TX, USA). RNA integrity was evaluated using the RNA 6000 Nano Chip kit (Agilent Technologies, Massy, France). Only RNA extracts with RNA integrity values ≥ 7 underwent further reverse transcription. All samples were reverse transcribed using the Superscript II reverse transcription kit (Invitrogen, Beijing, China), according to the manufacturer's protocol.

RNA sequencing library preparation, read generation and mapping

RNA sequencing was performed at the BGI (Hong Kong) for samples from Cohort 1 (n=40) and two CD33+ bone marrow cells from healthy samples (Stemcell; ABM032F). rRNA depletion was performed from total RNA with Ribo-Zero™ rRNA Removal Kits (Epicentre, Madison, WI, USA). Paired-end, strand-specific reads of 91 nt were generated on an Illumina HiSeq™2000. Alignment and mapping were performed using Tophat¹ against the hg19

genome and the mapped reads were assembled by Cufflinks 2.0.2². The Cuffcompare program was used to merge the RefSeq, ENCODE and UCSC human known genes freeze January 2013 into one gene annotation set for comparison with the assembled transcripts³. For novel lncRNA prediction, transcripts with a length >200 nt were extracted, according to the definition of lncRNA. Multi-exon (≥ 2 exons) transcripts and single-exon transcripts which recurred in multiple samples (≥ 3 samples) were then extracted. Assemblies that had long (≥ 300 nt) putative open reading frames (ORFs) were excluded. In order to filter out the known lncRNAs, the filtered assembly transcripts were BLASTed to find known lncRNAs from the ENCODE, Refseq and UCSC databases, according to the thresholds: identity >0.9 and coverage >0.8. Transcripts which did not match known lncRNAs were then used for protein annotation. The transcripts were aligned to four protein databases: kegg, nr, cog and swissprot, according to the thresholds: identity >0.9 and coverage >0.8. The coding potential of extracted transcripts which did not align with the protein databases was assessed using CPC based on six biologically meaningful sequence features such as ORF score, coverage, integrity, number of hits, hit score and frame score⁴. Known lncRNAs and predicted novel lncRNAs were then combined as the reference, and reads were aligned to this reference by SOAP2⁵. Among the 35046 putative lncRNA transcripts expressed in our samples, we selected only lncRNAs that were at least 90% identical to the reference transcript in at least two samples. Gene expression levels were calculated using the RPKM (Reads Per Kb per Million) method⁶. The raw and processed RNA-sequencing data have been deposited at the National Center for Biotechnology Information Gene Expression Omnibus (repository number GSE62852).

Statistical analysis

All unsupervised clustering and heatmap generations were performed using the «*hclust*» function in R and the Ward's agglomeration method. The partial least squares discriminant analysis (PLS-DA) and the sparse PLS-DA methods were used using the R *mixOmics* package. The “Perf” method, from the “*Mixomics*” package, was used to estimate the error rate of the model using leave-one-out cross-validation. Bootstrapping cluster analysis was carried out using the R *ClassDiscovery* package (1000-fold re-sampling).

Expression correlation between RNAseq and Fluidigm data was assessed using the Pearson correlation.

Event-Free Survival (EFS) was calculated from the date of diagnosis until relapse, death, treatment failure or the last received news. Overall survival (OS) time was calculated from the date of diagnosis until death or last received news. Disease-Free Survival (DFS) was calculated from the date of Complete Remission (CR) until relapse, death or last news. Surviving patients were censored at the date of last follow-up. For patients who underwent allogeneic transplantation, EFS, OS and DFS times were censored at the time of transplantation.

ROC curve analysis was performed to determine a suitable $-\Delta\text{Ct}$ cut-off value for each lncRNA. ROC curve analysis for EFS was performed 500 times on 13 randomly selected patients (5 *NPM1*⁺ patients and 8 *NPM1*-wild type patients) from Cohort 1. The final cutoff was taken as the mean of the 500 cutoffs. This cutoff was applied to Cohorts 1 and 2 to define the patient subgroups with high and low expression of each lncRNA.

The Kaplan-Meier method was used to generate survival curves, and these curves were compared using a log-rank test.

The Fisher exact test and the Mann Whitney test were used to assess the statistical significance of the differences between groups.

Cox proportional hazards model was used for EFS, OS and DFS to calculate univariable HRs. Multivariate Cox proportional hazards regression models were constructed for EFS, OS and DFS using a limited forward selection procedure. The following variables were first evaluated in univariate models: age; sex; leucocyte count; hemoglobin; platelet count; bone marrow blast percentage; treatment; ELN classification; presence of *NPM1*, *FLT3*-ITD, *DNMT3a*, *CEBPa*, *IDH1R132* or *IDH2R140* mutations; and the expression level of XLOC_109948. Variables with a univariate $p < 0.1$ were included in the initial multivariate models, and a stepwise backward variable selection procedure was applied.

For all analyses, p -values < 0.05 were considered significant.

All analyses were performed using the R 3.0.0 software package (available at www.r-project.org).

Quantitative real-time reverse transcriptase polymerase chain reaction analysis

Total RNA was isolated 48h post-transfection using the Trizol extraction protocol according to the manufacturer's instructions. Reverse transcription was performed with Superscript III reverse transcriptase (Invitrogen). Quantitative polymerase chain reaction (PCR) was performed with SYBR Premix Ex Taq (TAKARA) on 384-well plates using the Lightcycler 480 (Roche). The data presented correspond to the mean of $2^{-\Delta\Delta Ct}$ from at least three independent experiments, normalized to the ABL1 and TBP reference genes.

REFERENCES

- 1 Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* 2009; **25**: 1105–1111.
- 2 Trapnell C, Williams BA, Pertea G, *et al.* Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* 2010; **28**: 511–515.
- 3 Trapnell C, Roberts A, Goff L, *et al.* Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 2012; **7**: 562–578.
- 4 Kong L, Zhang Y, Ye Z-Q, *et al.* CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. *Nucleic Acids Res* 2007; **35**: W345–349.
- 5 Li R, Yu C, Li Y, *et al.* SOAP2: an improved ultrafast tool for short read alignment. *Bioinformatics* 2009; **25**: 1966–1967.
- 6 Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods* 2008; **5**: 621–628.

SUPPLEMENTARY FIGURES AND TABLES

Figure S1: Specific LncRNA expression profile in *NPM1*-mutated AML patients with normal cytogenetics. A Hierarchical clustering and associated heatmap of RNAseq data from the first cohort of CN-AML patients (n=40) with 33 lncRNAs differentially-expressed between *NPM1*-mutated (n=14) and *NPM1*-wild type patients (n=26). B Hierarchical clustering and associated heatmap of RNAseq data from the first cohort of CN-AML patients (n=40) with 12 lncRNAs differentially-expressed between *NPM1*-mutated (n=14) and *NPM1*-wild type patients (n=26). The heatmap depicts high expression (red, +1) and low expression (blue, -1).




Figure S2: Bootstrapping cluster analysis showing the stability of the groups based on the 12 lncRNA signature. Bootstrapping analysis results using the 12 lncRNA signature with Cohorts 1 (A) and 2 (B) (1000-fold re-sampling). Hierarchical clustering was used, with Euclidean distance and Ward’s method for agglomeration. The purity of the color corresponds to the stability of the samples in the specific groups. Analyses were carried out in R using the ClassDiscovery package.




Figure S3: RNA-seq quantification of XLOC_109948 lncRNA expression level in normal CD33+ bone marrow (BM) cells compared to CN-AML samples. RPKM, Reads Per Kb per Million.




Table S1: Patient characteristics

Characteristics	Cohort 1 (n=40)	Cohort 2 (n=134)
Female Sex		
No.	19	67
%	47.5	50
Age at diagnosis		
Median	67.5	55.4
Range	16-87	20-75
French American British classification (FAB)		
M0	0 (0%)	4 (3%)
M1	14 (35%)	38 (28%)
M2	9 (22.5%)	46 (34%)
M4	13 (32.5%)	23 (17%)
M5	3 (7.5%)	19 (14%)
M6	1 (2.5%)	0 (0%)
NC	0 (0%)	5 (4%)
European Leukemia Net Classification (ELN)		
Favorable	8 (20%)	46 (34%)
Intermediate I	32 (80%)	88 (66%)
White Blood Cells Count (x10⁹ cells/L)		
Median	30.5	34.5
Range	1.23-206	0.9-250
Hemoglobin level (g/dL)		
Median	10.1	9.35
Range	5.5-14.2	5.5-14.1
Platelet count (x10⁹ cells/L)		
Median	79.5	73
Range	8-735	10-489
Bone Marrow Blast Count (%)		
Median	79.5	73
Range	19-99	10-100
Mutational Status		
<i>NPM1</i> mutation	14/40 (35%)	80/134 (60%)
<i>FLT3</i> -ITD mutation	13/40 (32.5%)	58/134 (43%)
<i>CEBPa</i>	6/18 (33.5%)	16/119 (12%)
<i>DNMT3a</i>	11/40 (27.5%)	19/86 (22%)
<i>IDH1</i> R132	4/40 (10%)	11/83 (13%)
<i>IDH2</i> R140	8/40 (20%)	17/83 (20%)
Chemotherapy		
Intensive	25 (62.5%)	134 (100%)
NC	4 (10%)	0 (0%)

NC: Not Communicated

Table S2: Primer list.

lncRNAs	Forward Primer	Reverse Primer
n346526	GGAGAGCTTGGGTGAGGACCAC	AAGGGGGCTCAGCAGGTGATAA
n405918	AGCTTCGGCTATGGGACTGGTT	CGCATGATCTCTCAGTCCAGGTC
XLOC_005798	GGCAGTCAGGAAGGAAAAGTGG	CGGTGGCTGTTTCTCCACTGTC
XLOC_007987	AAACCCACCAACGTGACCAGAA	GCATCCTGGCAAATGAGGACAT
XLOC_010909	GACAAGGGGGAGACTACAAGAAGCA	CTGCGCTCAAGCTCGAAGAGTAA
XLOC_013842	GGTTTGGAGTGAAAGGCACATGA	CCAGGCAGCACTATCTGGGAAA
XLOC_018747	GCCTGGACAGATTACCAGATCATCA	AGCAAGCTGGAAGCTGAGCTCTT
XLOC_028763	CAGGCACCAGGAGAGGAGACAC	CACGGGGACCCCTGAACTTAAA
XLOC_028770	TCCGGTCATTGAAAAGTGCAT	AGGGTTTCCTGGCCAACTTGAG
XLOC_028776	CTTTTGGTGGCCAAATCCTGTG	ACGGTTTCACCCCTAGTGCAT
XLOC_028777	TTTGCTGCTCACCTGCTGTGAC	TCTAGGCTGGAGGCAGTGAGGA
XLOC_028779	TGAGCTTCCCCACTGCATGAAT	AGGCCGAAATGATTGTGATGTGA
XLOC_028783	CCTGGGCCAATCACTGATGTTC	GGGCAGGAAAGCTGTCAGTCAC
XLOC_034440	TGCTTAGTGAAAGATGCCAGACAAAA	TCCCCAGGCAGTAACCAAAGT
XLOC_034443	TGCACCGACTGACAGAATGAGG	TCCAGGGTTCCAAGATAGCGAAA
XLOC_047319	TCATCAGCCTCCTGCTCCACTC	TGATTACCACGCAAGGCTGACA
XLOC_050705	TTCCCGGTGGGTGTCATATCAG	CTAGCAGCCCCTCCCTCCATC
XLOC_060742	GGGAATGGAGAATTACCCTCTGGA	AAACAGGCCATTGACAGGTAGACAA
XLOC_063787	GCCAATGCCAACTTCACTCCAG	ACGCAGCCTCATACACCCATTG
XLOC_067985	GCAAATGGCCTCCAAATCAAAA	AGCCACAGATCCATTGCTGACC
XLOC_074912	CACAGGTGAATCTCCGCTGTCA	ATCCTTTGCTGGGGTTGGAAAA
XLOC_075298	TTGGGACTACCACCCAAAGCAG	GGTGTGAGCCATTCTGCTGGAA
XLOC_078730	GCATGCTAAGAGCCCATGAAGC	AGAAGCTGGCCCAAGTGTGTGT
XLOC_078731	GGCCAGGTGCAGTAGTTCATGC	AAACAAGGTTCCCACGGCTGAT
XLOC_080771	TACATGTGCCATGGTGGTTTGC	TAGGGGGCTAGGGGAGGGATAG
XLOC_083936	GCAATCTCGGCTCACTGCAACT	TGTGGCAGGTGCCTGTCTGTAG
XLOC_085385	TCCATTTTGGAGGCTGGGAAGT	TAGGGAGTTGGCCATCTGCAAG
XLOC_085994	GACCGAGATGAGGCAAAGAGCA	GAGCAATGGGGATAGTGCCACA
XLOC_087120	CCATGCACCAGGCACTGTAATG	TGGGTAGCACCTCTCCATGAGC
XLOC_091735	GCTGGTGGAAAGGTCTGTTCTGC	TGGCAGCAAGGATTTGCTAAGG
XLOC_091736	AAGAACCCGTGTCAGGCTTGTG	CCTCTGACAGCCAGCAAGGAAA
XLOC_109948	CCTGCCTTCTTGTCTCCACCT	GGCCAGGAAACAAATTGCAACA
Housekeeping genes	Forward Primer	Reverse Primer
<i>MLN51</i>	TAATCCCAGTTACCCTTATGCTCCA	GTTATAGTAGGTCCTCCTCCATATACCTGT
<i>5S</i>	ACGCGCCCCGATCTCGTCTGAT	GCCTACAGCACCCGGTATTCCC
<i>GAPDH</i>	CGGGAAGCTTGTCAATGG	GGCAGTGATGGCATGGACTG
<i>TBP</i>	GCCTCCCCACCCCTTCTTT	GCCACACCTGCAACTCAACATCC
<i>ABL1</i>	TGGAGATAACACTCTAAGCATAACTAAAGGT	GATGTAGTTGCTTGGGACCCA
<i>ACTIN</i>	TCCCTGGAGAAGAGCTACGA	AGGAAGGAAGGCTGGAAGAG
<i>S14</i>	ATCAAACCTCCGGGCCACAGGA	GTGCTGTCAGAGGGGATGGGG

Antisense LNA GapmeRs	Sequence 5'-3'	
XLOC_109948a	TCTGTGGAGCTGTAAC	
XLOC_109948b	CACTAGAGGCAGGAAC	
Negative control A	AACACGTCTATACGC	

Table S3: List of mRNAs differentially-expressed between *NPM1*-mutated and *NPM1*-wild type patients from RNA sequencing data (EdgeR analysis). Highlighted genes are those known to be deregulated between *NPM1*-mutated versus *NPM1*-wild type AML patients. logFC (log Fold Change), log CPM (log Count per million), FDR (False Discovery Rate).

GeneID	logFC	logCPM	PValue	FDR
Over-expressed in NPM1 mutated patients				
FOXC1	3,80	6,62	1,12E-07	2,49E-05
<i>SERPINB2</i>	3,76	7,24	1,89E-07	3,66E-05
HOXA5	3,26	5,57	8,13E-10	4,35E-07
HOXA6	3,07	4,56	9,94E-08	2,38E-05
<i>PTPN14</i>	2,92	5,29	8,63E-08	2,31E-05
<i>PTX3</i>	2,91	5,09	8,41E-09	3,07E-06
HOXB3	2,87	5,99	7,27E-10	4,14E-07
<i>KRT18</i>	2,85	4,45	2,07E-06	2,35E-04
<i>CD300E</i>	2,64	6,69	9,94E-05	3,71E-03
HOXB4	2,61	5,45	9,03E-10	4,57E-07
<i>IFIT2</i>	2,49	6,24	2,03E-05	1,24E-03
<i>NEU4</i>	2,44	4,85	4,57E-05	2,16E-03
<i>TP53INP2</i>	2,40	5,81	7,70E-11	9,70E-08
<i>PHLDA1</i>	2,27	5,60	7,67E-06	6,47E-04
HOXA7	2,26	3,60	3,46E-05	1,81E-03
<i>ETV5</i>	2,21	3,91	8,32E-09	3,07E-06
<i>IRAK2</i>	2,19	4,33	1,27E-05	9,31E-04
PBX3	2,14	6,04	2,35E-13	7,15E-10
MEIS1	2,11	6,82	7,39E-07	1,04E-04
HOXA9	2,00	6,99	4,75E-05	2,20E-03
Down-regulated in NPM1 mutated patients				
HGF	-2,03	5,91	3,09E-07	5,21E-05
<i>FZD6</i>	-2,03	3,64	9,55E-05	3,64E-03
<i>FAM105A</i>	-2,04	5,47	3,93E-06	3,73E-04
<i>C18orf1</i>	-2,08	5,28	2,28E-06	2,54E-04
<i>CEACAM4</i>	-2,12	4,69	1,54E-06	1,90E-04
<i>MYEF2</i>	-2,18	4,08	1,59E-05	1,07E-03
<i>STK32B</i>	-2,18	3,22	1,72E-05	1,15E-03
<i>LY9</i>	-2,19	3,59	1,79E-06	2,07E-04
<i>GATM</i>	-2,22	3,51	1,86E-05	1,20E-03
<i>SLAIN1</i>	-2,24	4,06	2,80E-06	2,93E-04
<i>TRPS1</i>	-2,27	6,50	3,57E-08	1,08E-05
<i>TNXB</i>	-2,29	5,50	1,01E-04	3,72E-03
<i>GNAI1</i>	-2,34	4,89	3,23E-04	8,04E-03
<i>COBLL1</i>	-2,34	4,75	4,49E-07	7,05E-05

<i>NRP1</i>	-2,41	3,99	1,51E-04	4,78E-03
<i>SPRY1</i>	-2,42	4,78	2,53E-07	4,44E-05
<i>PFKFB2</i>	-2,43	5,28	5,28E-09	2,30E-06
<i>IGJ</i>	-2,52	7,66	2,65E-05	1,50E-03
<i>PROM1</i>	-2,53	6,82	5,94E-05	2,57E-03
<i>LTF</i>	-2,57	9,21	1,05E-04	3,78E-03
<i>HLA-DQA1</i>	-2,60	5,94	3,85E-04	9,13E-03
<i>HIST1H3G</i>	-2,62	7,50	4,40E-08	1,25E-05
<i>C10orf10</i>	-2,62	4,43	2,90E-06	2,98E-04
<i>MN1</i>	-2,68	4,58	1,02E-05	7,83E-04
<i>STARD9</i>	-2,71	5,64	5,71E-09	2,36E-06
<i>SPARC</i>	-2,72	6,10	6,78E-12	1,54E-08
<i>FAM111B</i>	-2,79	3,92	1,13E-09	5,41E-07
<i>AKT3</i>	-2,82	5,86	6,18E-10	3,75E-07
<i>SETBP1</i>	-2,82	4,22	2,62E-07	4,50E-05
<i>NAV1</i>	-2,86	4,08	1,37E-08	4,46E-06
<i>RASD1</i>	-2,88	4,83	5,73E-06	5,28E-04
<i>PRR5L</i>	-2,91	4,98	2,42E-06	2,66E-04
<i>KLHL13</i>	-2,92	4,25	3,73E-08	1,10E-05
<i>ADAMTS10</i>	-3,03	4,61	1,74E-07	3,44E-05
<i>CD200</i>	-3,07	4,10	2,20E-06	2,47E-04
<i>APP</i>	-3,11	6,96	1,10E-07	2,49E-05
<i>ACY3</i>	-3,11	4,46	4,57E-05	2,16E-03
<i>IKZF2</i>	-3,16	5,30	5,29E-09	2,30E-06
<i>TMIGD2</i>	-3,25	3,92	3,44E-10	2,41E-07
<i>SLCO5A1</i>	-3,26	4,12	2,48E-06	2,66E-04
<i>HLA-DOA</i>	-3,30	5,61	1,80E-10	1,36E-07
<i>MLLT3</i>	-3,67	5,53	1,76E-20	1,61E-16
<i>L3MBTL4</i>	-3,68	3,83	9,27E-08	2,38E-05
<i>CRHBP</i>	-3,71	4,93	9,51E-08	2,38E-05
<i>CD34</i>	-3,80	5,23	2,31E-07	4,28E-05
<i>ATP10A</i>	-3,93	5,31	4,23E-10	2,75E-07
<i>BAALC</i>	-4,15	7,25	5,02E-07	7,62E-05
<i>BEND4</i>	-4,69	4,42	1,20E-10	9,93E-08
<i>LRP6</i>	-4,78	4,29	4,10E-11	7,47E-08
<i>SDK2</i>	-5,29	4,83	8,71E-18	3,97E-14
<i>TRH</i>	-6,04	4,54	8,84E-11	9,70E-08

Table S4: Sequences and localization of the 33 lncRNAs differentially-expressed between *NPM1*-mutated and *NPM1*-wild type patients

<p>n346526; chr9:139,534,589-139,541,618</p> <p>CCGTTGTGAGTTGCCGCTAGGCACCATGGCAGCTCGGGGGGACAGCCCTCCAGGAAAGCCCTGGCTGCCACTCTGCCCCCTGACTCCTGAATCCTGCCA GTCACACGGCCGACGGCTGCATATCGGGGAGGATGGCAGGCTGGGCTGTCTGAGGTGACCAGGGAATGCCAGACGCTTTGGGGTGAGGGTTTGGTTGCCGG CTTTGGGGCAGGCCAAGGATTTCAGAGGGGAGTAGGTCGCCGCGATCTTCTGGGGAGGGCCGGCTGCCGAATCTCTGGGATCAAAATGTGAAAAACCCACAG GGGGCATTCCCCTGATGACTGAAAGAAGAAGTGGCAGCGTACAGCTGAAGGGAGGCTGTCAGAGTGACCAGAGTGGCCAGTCCAGAGGAGACGGGTGGGGAAAA GTCTCCAGGAGCCAGGAGATGCCTTCAAGAAAAGAAATGAAAAGGAGTGTGACTGATGCGTGTGAGAACACGGGGACGAGCCTTGGGCTCCGTGGGAGAGC TTGGGTGAGGACCACCCGTGCCGCGGCGACCTCTGATCGTACCCAAAGCTGTGCCCTCCCATTTACGAAAAATATCACCTGCTGAGCCCTTGTCTGCTCTCT GGGCGTCACTGTGAGTGCACTGTGGAGTTTACGGACACCGGCCCGCGACGGTGGAGTTTACGGGGACCGCCCGCGATGGTGGAGTTTACAGACACTGGC TCCCGGACGGTGGAGTTTACGGGACCGGCCCGCGACGGCAGAGTTTATGGGACCGGCTCCCGGACGGTGGGGGCCACGAGTCCAGCATCTGCAGCA GAGTCGCGGATTCATGAGGTGACGAGTGTGCCACTGCAGACCTCGGGAGCCACCATCCAAAACCAATTGAGAATATTTCCATTACTTAGGAAAAAGCTTCTC CGTCCAGCTGAGGCGGGATGTCATAGACTTACCCTCCTACCCGAAACAGCCAAAAGCAAACAAAACAGACAAAACGCAGACACATGGCTTCCAAGACACGGGAC ACCAGGCATTAGAGGACAGTAACCCTGAGTGTGGAAACAGCCGTGCCCTAGTCAACCGTCTCACTGCCCTGGGAGGCAGTCCAGGCTGTGGGTGGGAAGGCGG AACCCAGCAGGTCAGTGGACCCCGAGGCTGGACAGACCAGGCGGCTCGAGTTTATGGACACAGTACCAGAGTGGAGAGGGTGCACAGAGAGGGACCCCT GAAGACCTGGATGGAGCCCTGGAGTATTTGGAAGAGCATGGCCCTGCCGATCCCATAAAGGAACTCCCGAGGGTGGGTAAGGACACCCGGAAGGATGAGAG GGAACAGGGCCGACTCCTGCAAGGGCTGAGGACAGTGTCTCTCCCATACGCCAAGCAGGAAATCTGTAACACAGGGCCCTTGGGTGAAGCCCTTGGGAAGGG CTTGCTCGGGGGGGGACGATCAGCCTGAGCCGAGCTGTGCTGTGAGCCCTCTACCAAGCCATAAAAGCAAGACTAGAAAGGATCAAACCTGCCTCAGATCACTT AACCGACGTCAGAGCAAAAGTGAAGATTTCCAGGAAGCAAAAATCCCGGGACCCAGCCAGGTGAAATTCACAAAGGACTGGCGTCCAAAAGGAAGAGGACCTGC CAGGCAATGGAAAAGCAGGAGAACGGGACCCATGATGAGAAAAATGATGTAATCAAACCATCCAGGGGTGGGTGCGGTGGCTAACGCTGTATCTAGCACTT TGGGAAGCCGAGGTGGAGGATCACTTGGGCCAAGAGTTCAAGACCAGATGGGGCAACATAG</p>
<p>n405918; chr9:124,217,319-124,262,306</p> <p>CACGTGCAGGCCGAGAAGGCAAAAAGGCCAGCCACTCTACCCGGGATTTTATCCGCTCCCGGACACACACACTCTACTCACGCACTCGCTCGCCGGCC TTCAGCTGTCTGTGTCGGGGCGGGACCGGCTTGGCGCAGCCCGCTGTGAGCGCTCGCCGGCTCCTCGCGCCCTACCCGCTGCCTCTGCCAGAGCAGAA GCCCGCCCGCCGCGCCACGGCCGGGAGGACGCGCTCCGCTCGGGCGGAGGCGCGGCTGGCTGATCAGAGCGCTGAGGCTTCCGCGGGCCGGAGCT GGGCGGCTCTGCTCAGCCAGCTCACCGCGCCCGCCCTCGCGCCCTGTTCTGCGGATCAGGAGTTGAAACCAGCACCTTCCCTTCTCTGAGTCTGCCT CCTTCTGCAGAAAGGAGCTCAAAAGAACTTTGTTGTTTGCCTTTACTCTGGGGTGAAGCGGCAGGAGGATGTGAGATGGTGAATGATTTGCTTCTGCCATGCT GGGGTACGGGTGGATCGCCCTAAACTCTCGGTGGCCCTCAGTAGTTTTGGAAGAGGACCAAGTCTTGTCTCCAGCAGTGGACCTGGAAGAAGGATGCCGG CTCAGGACTTCTACTGAGAAAATAATGAATGTCAAAGGAAAAGTAACTTGTCAATGCTGGTTGTCTCAACTGTGATCATTGTGTTTTGGAAATTTATCAACAGCACAGA AGGCTCTTTCTGTGATATATCACTCAAAAACCCAGAAAGTGTGACAGCAGTGTCTCAGAAGGGCTGGTGGTTTCTGAGCTGGTTTAAACAATGGATCCACAATTAT CAACAAGGGGAGAGACATAGACAAAAGAAAAGGAGAGAGGACCAAGGAAAGGAAATGACACAACAGAGCTCGGCTATGGGACTGGTTTAACTCAAACCTG AAGGAATCCGAATAACTAACTGGACTTGGTTTTCTGACTCAGTCTTCTAGAAGACTTGAGAGATCATGCGGTTAAGGAGTGTGTAACAGGGGACCCCT GTTGGGACTGCGAGATTCTCAAGGGGAAGGACTGGGTCTCATTCTCCCATCTCAGCGCTTAGCAGGATGACCTGGTATAGAGCAGGGAACTGGGAAATGTGGGTCA GGGATCAGACACTCCAGTTGGGTCTTTTATAAATAAATGGCAAAAGGCTCCATACCCTTCTCCTTCTTCTACCCTCCACTTTATCTGCAAAATGGGAATGATGA TAACACCCACTTCATAGAATGGTTCATGAAGATCAAATGAGAGAATAAAAAGTCAAAGCACTTAGCCTCTGGTGACAATAAGTATTAATAAGTATACCTATTCTCTTTT CCTTTTTTAAAAATAATATTACAAATGTCCAGCTTATACACATTTACAAGACTTAGCTAGTGGGCTATGTTAGAGCTACTAAAAGATCTTTGACAAGCTAAAACCTAAAGAT GCAATGAATGAGGTGTAACGAACAAGAGAGTTTTAAGTTCAAGAAATGGTTACAGAAGTATAAGACAGCTGTGTGGGTGTTTTTGGTTTTTGGTTTTCTGGTTTTACAATCT CGTCATTAAACAAGATGGGAGTTTTATAGAATAAAAGCACCATGTAAGCTACTAAAACAACAACAAAAGGCTCATCTTCTCAGTCTGAATTGACAAAATGCC AATGCAAAATAAATGATTACTTTTTATTT</p>
<p>XLOC_005798; chr1:25,188,258-25,189,524</p> <p>GGCAGGAGCTGGTGGCAGCCTGTGCCCTGGCATGGGGCTGAAGTCACTACAGGTCACCGATACTGGCAGTCAAGGAAAGAACTGGATGTGGACCCCTGGG CCCACGAGGATGGGGTCCAGGTGACAAAACGTCACCTTTTCTGACAGTGGAGAAAACAGCCACCGAGTTTTCATGCAGGCCACAGGGAGGAGCTTGTCTGGAG AATAATACAGCAAAAGAGACTGGCAGTGCAGCCTTGAACGATTCAGGCCGTAGCTCGCCCTCCTAAGCACCTTCCAAACTGCGGTGCCTCTGTGGGAGTGT GGCAAAGCTAACAGCAGCTTCTGCCAGAAGGGAGTGCCTGTGAGAGCTGCGGGCACCGTCTAGGACAGGGATGCGGTAAACTCTCTGTGTTGCTGAAGGAGGG GCCTGTGGGGAGAGTGACGGGCCCTGTAGCCCCAGAAATCTGCCCGGTCACCTCCACCTTCTCCTTAAAGGAATGTGAGCTGCAGGCTTCAAGAGCCCCAGATG TTGGCCACCAGCTTTGAAGCTGCCACAGCCTTCCAGGACAAACTGATGGCCGCGCCAGGGTAGGAGGAGCCAGCAGATCCCCACCATTTTCTGGAGGAG TCCAGGACAAGTCAATTTCTAGCCTATGCAAGTCCGCTTGTCTGGCCGGGTAGCCAGGATGGCCAGTGGCCATGCAACCTCACGTCCTTCC CGCCGACCACTACTGCGTATGGAGGGGGAGCGATACCACAGAAGTTCTGGCACCTTCTGATCTCCTTTGCACTTCCAGT</p>
<p>XLOC_007987; chr1:151,915,378-151,918,279</p>

AAACTTTAATCACAGGAAGAGGCTGTTGGCACCCGAGAGCTGCACATAGCAGTGCAGAAAGTAAAGAGAAAAAGGGGAGGCCAAAATAACATAATTACTTCTCA
CAGCTAGGATATGTCTACCAGATTACACTGAACTACCTGAGGATGACTGGAACAGAGATAGTGGTAATTAATTAAGGCTTACTATGAGGCCTCTTAGTCTTCAa
tcattattcattttaaagatgaagaactcagatcaccagagcttaattgtatgtctggtgagtaacaggccaggatcaagccatcagcttctccaggccaccacccttaaccattatgTCTGATGACCTCGGGTTATAG
GAAAGGAGAGCCCTACAAGTTATTGATGGATTTTGTTCATTTGTTTGTCTGCTGACTATAGTAAATTAATCAAGGCTTTAAAGACTAAAACAGGATGGATTTCTAA
TTTGACAGTTAACTGCTAAGGGAGCAAAAACGAATTGTGTAGTGGAGACCTGGCTACCAAGATGGACATGTTCCAGTACAGGCATAGAGAAAGTTCTCTGTTTGGT
GCCATCAACTAAGTCTTCCCTATACCTGGCAGTGTACCATCTTTCACAGTACAGATTCTGCCACTTTGGCCAGGCGTCTCATTAGTCCCACCCTCATCACAAA
AGAGTCTACTGGGACAGGTGAGCACAACCACCAACCTGACCCAGAAGCATAAATCACAAGAACCTATCCTGCTGGCAGAGGGGAGCAAGGGCCACCAAGGACAGCC
TCATCCCTCGGAGAAATGTCTCATTGCCAGGATGCCTCATTGGCTGCTGAAATTTGGTGGACTCAGGAAAGTCTATTAGCTCTGAGTCCAGAGCTGTTGTTTGGAG
TCAAGATGAAAAAGGAGCAATTTACATTTATCTAATGCACAGCTAAGAGTGGAGGTTGGGTGAACCTGATTTCAAAAAGCAAACTGAGTATTAATTTACCCACTTTT
TAAAGCGCTGACGTGATGTAAGGATGCTGCTATTGTTGGCTAAACAATTTCTTAGGTCTAATTTGGGTCTAATAGGTTGACATGAAGCTCCTCTGGGCTCACAGCATTG
TGCTGTAAGCACTGTAGCTATGCTGTGTCAACGCAAAAGCATCGTCCacagtaagcaagtgtagagllttgtcaccacattagttgctcctGGAGAGTCAAGCAAAAGCTGCTGCC
AGAAATTCATCTTATCATCAGAGTACAACCTTcaggctgctggatctatgccaccctcgcattactagctgtgtagcggcagttacttccctctctgctggttctactgtaacaggacagaaaaatlttcta
cttttagggctcgtgagatcaagaagtlaattcatgccaactgctgtaagagttcctggcaTGTGTTTGCACACACTTCAATCTTGGATTAAGAACTTGGCATTTCAGTTGAACCTACGGTATTCT
GCCTGAGCGCCCTCAGCCTGCCCTCTGAAATAGGGTATGTAGGGAATACAGTTTGTCTTACTTACTGGGACACTGCTATATACAAGGCCATGTTTATCTAATTTCTCT
CTATTTTGTCTATGTACAGTTTTTCTAAGTATTTACAAGCAAAAGGACCTCACCAGAAATTTTGGAGGCTTAACAGGGCTAAGTCAAGCATGATTACTTTTAAAAATAATTC
TGggccaggccacagtggttcatgctgtaactcagcaacttggggagctgagtgaggatcacaagaccaggagttcaagaccagcctggccaaatagcaaaacccaccctataaaaaatagaaaaataaaaaGA
AATTTCTGATCAGATTTCCAAACCAAGCCTGTATCATGTTCAAAACAGGGAGTCAAGTGGACTTCAAGCAAAACCAACCAATAAGCCACATATTGCAATAAATTTCACTA
GTGCAGGGATGAATGATTCTGTGGAATGAGACCTAATTCCTGTTGATTTAATTCACAACCTCCTTCAGAGAGAGGGGTATAGGCAGCCATCAACCTCCTCATTGTCCCT
TGGAAatcttaaaaggaagcagtaggtaatagctgggaagagatgagcactgggcaactgctgctgcccacttggcaagcaaaacacactatllacttgaatgaalattatggggagggggtctgtgagggaaggg
gctgaagtcocccaaatgctactggttctggcaactTTCCTACTTAAATGACAGAGTGTGTTAGTTAAATCAAATATTTACCTTAATATGTTTAAAGTATTTTGGAAATTTCAA
ACATTTCTTCTTCCCTTCCCAAATAGATCAACAGGACCTCCTGGAGTATTTTAAATTTAGACTTTTCTAGATGATTTAGAAAAAGGAAAGACAAACCAATAGAAA
CGTTGTTTACCAGAGCCATCTTCTGATTCAAGGACTTCTTTTGTAGTATGTAACCTGATGCTTCAAGTCAAGGATGATGACAGGCATGAAAACACATTTCTTTCTACTAGCTTGAAA
CATTCTGATGAATGGCCCTAAATGTTTCCGGTGAATGGCTAAGATTACTGATGCTCTACTTCAAGTACAGGAGTCTTATAGATGTGGTGTAGTAAATGCTCAGATTG
GGTCTTGTCTTTCTATCTCCTCCACATGAGAAGGACTTGACCCTGCTGGCTCTTATCATTGCTATGTGCAGTATTGGGTAAGATGTTCTGTGTGCCAGGCACCAGT
CAGTTCAAATGCCTTGGAGTGTGATCAAGTACTTaaagagagatgcccct

XLOC_010909; chr10:61,810,320-61,845,161

CAAGAAGCCTCAAGTTATTTGGATCATATTCAAAAGTCTGCGCATTGAAAATGGCTTCTAGTTCTCTGAACTCAATTTACTAACCCCTTAGAAAAGATCTGATGACGAAG
TAATGAAGCAAGGGGAGACTACAAGAAGCATTCTGTGGAACCTTACTACGCAAAAGCCATACCTGTCAATCCAGTCTGATGAAACCCACCAGTACTCTTCGAGC
TTGAGCCGAGGACTCTAGGTTTCCACTTGATGCTCAATCTGCCAACCTGTAATTTGAAGACATTTCCAGTTCTGCTTGAACACGCTTAAGAAATAGCCTGTACTTTTT
CTTCTGCTATCTCCTCAGACTCTACTCTTCTTCAAGTGAATGTCTCAATAGAGATTTAGTGTCTTCCATCATCTCCTCATCAGGACCAGATTTTCTTCTCCT
GCTGCTCAGAGCTTACTCTAGTTTCTAGGCTCTGCTGGTTAACTCTTTGGGGACCCAGCAAAATTTCCAAAGGTAATGAGGATACTCACTCAGACATACATTCTC
CAACTGGCTCTCATCTACATCCACTGCTCAGGCATTTCTGTTAAAGGCACTGAGTCTCCAGTTTGTCTCTTAAGGAAGCGTCTTCTGCAGTACGACTGGAGGT
CCATCTGCGGAATGCTCTATGTTCCCTGGGAAGGCACTAGCCATCACTCAGTCTACTAGGGGTTCTAAGGGGAGATTTCTATGCTAGAGATATCACTAAAATAATCA
TCTTGTCTGGAAGGGCAGAGAGAAAAAGTCAACAATGGTCTGGTCAATGGTGAAGGAAAGGAAATTTTCAAAAAGTTCAACGAAGAGGAGAGACAGGAAAAAGCAACAA
ACCACAGTTTCTGAATTTGTTGGTCTACAAAATAAAAGTCTAATTTTTCCATCAGTCCCAGATTTCTGTTAAAGATGATTTACCTTGATGGAAAATGGCAGTCTATTTTTCT
TTGAAAAGATAAAAAGTAAAAACAAGTTGCTGTCTCCTTTGAAACATCGCAAGGAAGATTCTACGGGATCATTCAATTTGGCAAAAACAACAACCTTGGCCATATATGG
AACACATATCAATTTCTGTACAGTTGGTGGCTAACCCACAGTTTCAAAACTTGTAGGCACTGCAAGCCAAAATCTGAGCAAAAACAAAACAGAGATGAAA
ATGTGGCTATTTAAAGCCAAATCTTAAAAAAGACTACAATTAAAAAAATCAGAATATGAAAGGAACCTAACCAAAACGTTAACTTGTCTTTAAACAGCAAGAT
GCTTTTTCGATGTATCAACACAGAAACCCCTGTTTGTATTTGAGGATAAATTTGATAAGCAAACTACTACGGATTTTTTTCTCACAACAATTTTTTATGATTGAACA
CAACAATTTTACTTTCCAAAAGGTAATAAAAACTAATCTTACTGCTTTTGGAAATCCTTTATTTCCATACCTGGCTGAAACATTTGGTTGTAAGGGAGACAACTTTTT
ATAAACGTCAAAAGGAGTTTCTGATGCTTCCACTGAGCAGGCGAAGTGGCCCTGAGAGAAACAACAGCAGATATGTTGACTTTATCATGGGAGATGCTCCTT
GAAAAATTTTATCAGATCCTGTTCTTCTTCTGATAGCCACAACCTGGCAAACTTCAACACCTTCAAGTTAATAGTGTGACTAAAGGTAGTTTTCC

XLOC_013842; chr10:54,246,152-54,246,835

ATTGAAATGAGTTAGTAGCACTTAAATCTGGGGAGCATATTTGATTTTAACTGATGAGATTTAGCTGCTGATTACTCAATCAGCTGTGGTTGGAGTGAAG
GCACATGATAGAAACATACCATGTAATTTCTGCTATTCTAAAAATATTCAGCATAAATAATTTCCAGATAGTGTGCTGCTGGTGagacagcattctacatctccagtcatttcaagtcctcatt
ttctctgggttaaacagagttgcttctcactcctggtgagatgcccccaataatacatatttctcctggtcaatgctctcttaaaatgatATGATTTCCCAAAACACTTATGTTCTTAGCTCACATCAA
TCATATCTCCATTCTGATTAGATTACAAGCCACTGAAGTCCAGGACCTGAGTCAATTTCTTATCCCTCATATCTATTATAAAATCCTAACCGAGGATCACAGTTTGA
AAAATGTTGTTCAAGAAAGCTATATATGATGATCCACATACATTTAACTTTGTACAGACAAGAATATACATTTTCCAAACATTAATCTCCATAATTAGCCACTGTTTT
AGCTGGGCCACCTACCATTTTGTATTTGCTTTTCTGCTTGTGGCTTAAATTAATCTTAAACAAAATAACCAGC

XLOC_018747; chr11:58,756,982-58,767,516

aattcagctgtaaatctatcctggcctgactctttgggtgtaagctataattatgacctatctcagagcaatgtattctatcagagattcaactctctcgtgattcttgaggggtgtagtgtagaggaattatccattctctagattctagttta
ttttagcaaatatgTTTTATAAAGTATTTTAGAGTATATAAATTTGTGTTTTATGTTCCACAGAAACATATTTTATAGGAGTTAATCTTGACTATCTAAAGGTTATTGTGAACTAG
TTCCAGCTTTCTCCAATACCCTTGCCACGAGAAAGTAACTAAATCATGTATClattctctctcttattataaataaaggtaalgctgaggaatatacgagatttctgatactctcttattctgagggaaa
aaacACCACTAAACTATCCCTCTAATCTGTGTAATAGATTAGCTACACTTTCTTCACTAGCAAGATAAAATAAATTTCCACATTTTCTAGTTTACTTTGTAGAAATAAACTCTCT
GTAATTTGGACTGTATTCAACGAAACTTAGTAAGTTGAATTTATGCCTCAGGTATGTTCTATGCACTGAGTGAAGAGTGGAGATAAAATAAGAAATTTAGATTTTCCTTTA
CTTTTTAAATAGGTTGTTGCCCTCTTATATTTTATCTATGATGCAAATGTCATATCCTAATTTCTAGTTTTATGTTTAAAGCACACAGTGCCACTTCTATGATTCAAT
ACATTTGATACCCTTGAATCAATCAGAATACTGCAAAATTAATTTTCTAAAACAATGCTTTATCGTATTCTCTGTGTAATCATCAGTACAATTCCAATGA
CACTTAAAAATACTCATATTAACATCTTCTTCAACAGAACCATGATGAAGGACAGTGATAACAAATATCTGACAAATGATGATTATTTCTCATCCATGGAAATTTTC
CTTAAATAAACTAAAGGGCTATTTTCTAAAAGCCAAAAGCATTGCTTACAAGAACTTTTCATCATGACATGGATAGACACTCAGATTACATACATTCAAAGGGAAAGTGTCT
GTATTTCCCTTTCAATCCACCCTATTCTATTGTGTTATCTTCTTAAATTTTCTATCTACATTCTTCACTTCTTCCCATTTGCCATTGACCTATGTTCTGTGATAAAAAATTGC
GCAATTTGGAGTCTTTGGGAGGTTAGGTTATGCCCCTTTACCCTTTTCAACATAATCACACATAACACCCCTCTCCATATTTGTAATTTTCAATATACAGAAAAAAGTACTA
TAATTTCTTCAACATGCTTGATATTAATGATATATGGGAAAACAATTTATTTGTGACGAATCTTCAGATAACTGGGAAAAGCCGGGAAAAAGAGAGATCTGGTGGTT
ATCAATGACCCTATGTAATAATTTTATTATGTAAGCTGTCTTCACAAATGTCTTATGTATGATCATTAGAACTGTTTTATATATATGTAATTTCCACATTAC
GAGACATTACTTTCACAGTGAAGTAATCCTTTTTAACTGCCAC

XLOC_075298; chr4:89,336,836-89,376,492

agctttaaataagccactcctccactgcaatgaltcacatgctcaatgtcttggtcatgagacaagaacctgatttagctgagcaaggagcaaaatcctgcatcagtagGTTAAGGAAACAGACAGGATCCAA
GTGTGAGAAAGCCACCCTGAGTCTCTCAGAGTcaaaagacacaacaaagccgacaagtggaattggaaatggaacaaaagGCACAAAGAACATCAAAGCATAAATCCTTCAGGTTATc
agcaatgacalcctaaagaatctcagaacttggcaccacccagggcclaccggatcagaatctgaatlltaacaagatcagATCTAGTCAAGAGTCCAGTCTGATTTCTCTTTATTGGACTACCACCC
AAAGCAGAATGAGGATGATGAACCACGCCAGTGACTTCTGGATACCACCTGACTCTAGAcctgaaattccagcagaatggtgacaccaactggtcgaagacccccaaggaactcagctgct
aggaatgcagttcctccactcctcctcagctcaccctcactcctcaaccaatcagtgatcacacacttaggcaactggtcagacaccccttaaaacccactgcaaacctctggaagcatalttgaglltctctcactctcact
ttggtttccctcaatataaattctctctgctgcaactcctcttctcagttattgtctctagctgcaacaggaaatcgagactGTTGGTCTTATAGTAAAGctcacagaatagatatacaaggatcgtgatacaaaaaacccg
gcaac

XLOC_078730; chr5:120,504,656-120,505,782

CAATAGACACTACAGCATTAAATAACATGTTTATAGGATAAGTTTTTATTGCAATTATCAATGGTGATTAATTAATAGCTTTACAAGGGATGTTTTGGTATTTTTAGCTA
ATCTTTGGAGTTGGTTCTATATAACATATGCATGTTTAGACATTTAATAGTATTTTCAAGTAAATATTACAGTATTTAATAGGTTAAACATGTGTGCTTGTCC
AACACAAGGGCAATTTTTCTAGATTACTTGCCCAATTAATGTCTAGTAAATCCCCATAGAAGTGTATGACTTTCCAATATCCGAATATACTCGTTGGTTTTACTATGT
CAATACCCTGGATTGGGAGGTTAGGTTAGTGGGACTGTACTGTAATTTTCAAGAACTTTACCTTAAATTAATAGTTTGCATTAGTAGAGATTGTAATTTACATAT
CCAGTTAGCACCTGCATTCTGTAAGGAGACACCACCTAAGCTTTCTGGTTCTATCCATAGCCCATGTTATAGTTTCAGAAGGATACACTCGGACTTCCATTTAAA
AAGATTGGGAAAAATGGGCTTATTTTTCTTGGGCTACTAAGAGCCCTTAAAGCTAAATTTTACAGATTTTTTTTATTTCATCCATTGGCCCTTCTACATTTAT
CTTGCAACACACACTTTGGGCCAGCTTCTGTTTTCAATTTAATTTGTTTTACCTTCAGCTAGTTTTGGGGTAAATCACATTGAGAACAAAGAAAAATCGGTTGT
TTGCCAGAGTTCAATTAAGTATAGTGTCTGTGCCAAGCAGCTGAAAGACAGCTTGTGGCCAGCTCCTTTTTCAACCTCCTGGTAAACAGAGTCTGATAAATCTGAT
ATTAACAATAGCATTATCAAATTAATTTTAAATCCTTTCAACCTATAATTTTAAAGCAAGATATAAGAACAATTTTTTTCTATTTAGATACCATGGAAGTT
GTGGCCACTAACCAACATTTCTCATATATAAAATGATGAGTTCTGGATTTAAGGCCAGATTCTTTCACTTCGACTTTGGGAGCCCTAAGTAAATTTAATTTCAATTTATGT
CTGAAGTTGCATGAACAC

XLOC_078731; chr5:120,513,301-120,514,526

aatctgctcaatgcatagttgaattttgtaaagctataaattctctttatacagcagtagcaggagatlltcaatagggaAAAAatllaagllttatagctatatctacttagctaaagcctcactcaatgctcaatcctgtt
gcacctgagataaattgtagaaatacactgcaataacaacacaaatgtaaatltaaatcaatlltagaaagaatllttagaaataaatttaaagattlltagaaataaattctactagtaggattcagacacagctcatt
ttgttgaataaataacacatcatctataaalaalgaattgtaacatlltcttggggtggggcggtggtglaaglgtagtagatccagatattcaaaaacaggtctaitgaaatlltagagatacaaaataaataaATACAGAGTCA
GGGTTTTGAAAGTTTAAAGCAgcccaggtgtaggtctcctataatcagcattttggcagactgagaggaagattgttggagcttaggagttcagatcgccggtggaacctgttctctcaagaaattgtaaaatll
gccaggttggtagtgcctctagcagacttaggagctgagcgtgggagatcaactgagccatgaggtcaggtcaggtgagcggtagcacaaccactgcaatcctcaactggtgcaacagtgagacccatctcaaaaaCA
ACAACCAACAAAAAAGATTGTTGACCATTTAAATTTTAAAAAGCTAGTTTTATGCAATATAATTTACTCAATTTCAAATAGGCAGAAATGAAAAATGATACACACT
GTTGAAAAATGCTTATTAGACACCAGGATTGAATCTTAAATTTAATTTTAAAGGCATACTAGACTTATTTTATTAATGTTTGTGTTTCACTGAGGTAGGCCA
GTGCGAGTTTCAATGTTGATGTTGAGTGTCTTTCAACTCAATCCTTTATCAAACCTCCAGAGACAAAGGTACTGTCCAAGTGTAAATAAAATGAATAAGTCAGG
ACTTTAAATGATTTCTCTTTAGCAAACCAATAgcttagcaggtgctcagggacagctcttagccagcagctgtggtllcaaatcagc

XLOC_080771; chr5:56,021,002-56,021,770

CATTGCCATTTATGATACAATGTTTTGTTTTACTTTTTAGTACTGATTTCAAATGAGAAGTGGTTCCTCGTGACATTTTGCTGACAGACGAGACTTTGCAC
ACCCTGAGGCCATCTCATACTGTGAAGAGGATGCCGGCTTCAGAAACCTCTCAGAGTCAAGTTGTCTCGATTCCCTTTGGCTTAACTTTGCAACACTTCTTTCTC
TGGCTAATTCAGACTATGAATGGTCTTGTCTATGGAAGAAATGTGATCTCTGTTTAAAGACATTTCCCAatttttttttttttaaatactaaattggttttaaatactaaattggtt
aaatattattaaacaATTGCACTCAGATTTTCACTATTTTAACTTTGCAATAGGATACAGCAAGTACTTTCTCAGACATTGGGTGAAAAATACAGAGACTCCAGAACCTTTGAG
ATTGTTGAAATGTTGAAACTGTTTTTAGGTAACATACATTAACCTTTAGAAATGCAACCCGGTGGAGCCCTTAGCTGTTTTGAGCTTTCTGCACatcagtgcaagaagtg
caggttggataggtatagtcagttggtgtcgctcaactcaacccgctcactcaactaggtatcttcaactctcctcccttagccccactcccgacaggtccgggtatagtttccccctgtgctatggttcaactgtg
caactccact

XLOC_083936; chr6:27,863,983-27,864,675

agtgccgcaactctgctcactgcaactcctccctggtllcaagtattctctcaactcctgtagagcagtaactacagacagccgctcagcagcagcaglaattttglttttagtacagacaggtllcaccatgtgcccagcct
ggtctgagcctcacaagttcgggattacagcgcgagccactgcactcgtgtcttgggggaacacaagaagtcocatacaGCACCTTAAGACCTTTTCATGCTTTATCCCCGACTTTCTATTCCAAGTT
CTCCCTTTATAAATATCTACATTTAGCTTAAATTTGCAGATAAAGTGCAGATTATGATATTCTTAAACCGAAGTAAAAGTGCAGTTGTCTAAACAAAGGCCAGCAGCATTAG
AGCAAAAACAGCTGGATATAAAAGCACGccttactctataagagaggtgctatttctgtaaacaccagcagctctgcatlltccattttccagttttagatagatactgaccaagatataatllcactlltctaatl
ctgctgtaagaacaacatagcaagacatattgataatgccaaactaaatggaactaacaggaagcaggtgtaactgagaaactggaacaaaactgcaatttgattcactgattctccct

XLOC_085385; chr6:119,685,366-119,687,007

actcgtttatagttctttgctgtggagaagctttaaagtaatagatctactgtcaatgttgctttgttgcattgctttggtgtctttgtcatgaatcttaactgttccctgtgtcccagatggttccaagggtgctccagggtttatagtttgggt
ttacataaagctttaaaccalccagtgagttttgtataggttaaggaagcgggccagctcagctctcgaGTAATTTCTTTTAAAGTGATAACAGTCTTTGTAAAAAGCCCTAAAGTCATTTAGTGT
TCCCACCTAAATAAATAAATTGATCACTTGCCTTACAACAGAAAGCCCTAATCATTGTTTTCTCTATCCAGTCCGATTGGTGGTTTTCAAAGACACACTCAAGGAAAG
AATTTCAAGTGTGGGAAGGTTAAATATAGGACCAAGAAAACAAGGCTTCTGTGCTGAGATGGCATGGAATACTTTGACCATTTCCAGCTAGCCAGGAATGAAAG
AAATCTGGTGAGAAAAGAAATGAACCGACCCATTCTGGCACACAGCTCAGCACTGCAGCTGCAAGTGAAGAGAGGACTTGGGCCACCAGGCTGACGAGAGACAGA
GGTGTGGCACTGGGTGCATGCAGGAAGCCTCCTCCAGACAGGGCCCTTGCAACTCTTGCCCAAGCTAATTTCCAGGATTGCCTACCTCATACTTAAAGAAATGCTA
GTACAGTGTATCTCTGATGTCTCCAGAGGAATTAGATGTTATCTTCTTCACTTCCATCTATACTACCTtagtttctatcaaccacaatlaaccagctlaagagaacacaatlatcctctc
ttaggtctgaagtccaacacaatataccaagctaaaatcaggggtcggcggggcgtgggggtcttacctggagatctgaggaagaaccgtgctcaggtgtgctcaggtgtgctgactcattccaatgagctatagagctggtgct
tgttctctgtggctgtagaggactgctctcctctgctctagctccctccatctcagagccagcagcagcagtagatctttctttttctttttctgagagcggagtttgcctgtgtcccaggtggaggggcaatggcgcagctcggctcagc
caacctgctccccgtcaagtattctcctaccttagctcc

XLOC_109948; chrX:45,688,377-45,689,937

CGATTAATTCCTTATATGGTAATGTACAAGTACAGGGACTGGTGCCTGGTAGTAGCTCAGGAAAGTtcctccctccctcactcctccctcctctctgtcatccccctgctctgtctccacctcct
tgttactcttattctttctgtccccctcctctcttGTCCCTTAACTCCCCAGTTTGTGCAATTTGTTTCTGGCCCTCCCTTAGGGACGCTGATCTGGCTTTTGGCTCATCAATGACCTAAC
GGTGGACTCCAGTGGCTGTTTCTCAATGACACCTGTCTGTTTTAACTTGTGCCAGTTTCTGGTACTTTTTCTTCTTTTAGCCCTATATGATCCCTTTCTTCTCAGGA
CTAGGCTGGATTCTCTTCCCTTCTAGTTTTTAAAGTATGCTATTCTCCAGTGAATTCAGCATCAACCTGTAGTCAACTCCCTACTCAGCCGCCATCTGTGATCAC
CAGCATGGTGGCTGCTTCTCACACCTTGACACCATGTTGAATCTTAAAGGCTTCAAGCCCTTGGCTTCTTTTTCTTCCATAAACATTAGCCCAATGCACTCTTCA
GAGAAGTCTTACCAGCAACCTCAGTTACAGCTCCACAGAACTTTAAAGGCTCCCTCTAGTAGCCCTGATATCAGTCTGGGATTTCACTTCATCCTCTCCATtttctcgtcct
ctagtgggtgagtcctgtgagcagagctgtctgattattctatgggaactaacctccctcagctcagctgaataaagAGAGAGAACAACTCATTCAATTAAGTACACTTCTATAGATAAGTACTGCTTTAAAGAG
ACTGAATGTTGATTAGCCACAGGGAAAGAGAAAAGTATAAGATCAGAAAACGACTTCATGGTGATGTTTATGGGAATCTATGGTATTAGCCAGtttataatataaattattata
TGAAGTAGCACAGTGTGATAGGTAGAATAATGGCTCTCtgcgtggtttggatalggtttctcccagcaaaactaagctgaagttgtcccagtgtagagggtggggcctaataatggggaggtgtggatcataggggt
ggatcctcatgaatgggtgggtcgtttcacagtacagagttgttgcctcctagactggatagttcccacggagaatggatagctcctgagtgagtggtgtataaagccaggacccccaggtttctgctcacaagctctcctttt
gacctctcgcagctgtgtagcaagaagcattgcccgaagccagggccatcccctgaaacttttagcctgagagctgtgagciaagaaaacctcttataaattgacctgctcaggtttgtttttttatagcaatacaaaatgga
gaagacaAAATGGCTAAGACAcctccaagatgtctatgctcctaactcctggaacctgtgagctgattatagcgaaggggaatgaagttggaattggaatgaatgaagct

Table S5: Validation of RNA-seq results by Fluidigm. Table shows Pearson Correlation r values for each of the 32 lncRNAs comparing RNA-seq and Fluidigm data, using the CN-AML Cohort 1 (n=40).

GeneID	Pearson correlation
n346526	0.89
n405918	0.94
XLOC_005798	0.92
XLOC_007987	0.94
XLOC_010909	0.96
XLOC_013842	0.83
XLOC_018747	0.80
XLOC_028763	0.84
XLOC_028770	0.91
XLOC_028776	0.93
XLOC_028777	0.92
XLOC_028779	0.90
XLOC_028783	0.83
XLOC_034440	0.87
XLOC_034443	0.94
XLOC_047319	0.81
XLOC_050705	0.82
XLOC_060742	0.64
XLOC_063787	0.92
XLOC_067985	0.96
XLOC_074912	0.86
XLOC_075298	0.90
XLOC_078730	0.92
XLOC_078731	0.87
XLOC_080771	0.93
XLOC_083936	0.89
XLOC_085385	0.17
XLOC_085994	0.48
XLOC_087120	0.94
XLOC_091735	0.88
XLOC_091736	0.75
XLOC_109948	0.90

Table S6: Patients selected for clinical analysis (CA)

Characteristics	Cohort 1 CA (n=25)	Cohort 2 (n=134)
Female Sex		
No.	9	67
%	36	50
Age at diagnosis		
Median	61	55.4
Range	16-75	20-75
French American British classification (FAB)		
M0	0 (0%)	4 (3%)
M1	10 (40%)	38 (28%)
M2	7 (28%)	46 (34%)
M4	4 (16%)	23 (17%)
M5	3 (12%)	19 (14%)
M6	1 (4%)	0 (0%)
NC	0 (0%)	5 (4%)
European Leukemia Net Classification (ELN)		
Favorable	4 (16%)	46 (34%)
Intermediate I	21 (84%)	88 (66%)
White Blood Cells Count (x10⁹ cells/L)		
Median	32.1	34.5
Range	1.23-206	0.9-250
Hemoglobin level (g/dL)		
Median	9.9	9.35
Range	5.5-12.8	5.5-14.1
Platelet count (x10⁹ cells/L)		
Median	78	73
Range	8-367	10-489
Bone Marrow Blast Count (%)		
Median	84.5	73
Range	19-94	10-100
Mutational Status		
<i>NPM1</i> mutation	9/25 (36%)	80/134 (60%)
<i>FLT3</i> -ITD mutation	9/25 (36%)	58/134 (43%)
<i>CEBPa</i>	4/14 (28.5%)	16/119 (12%)
<i>DNMT3a</i>	6/25 (24%)	19/86 (22%)
<i>IDH1R132</i>	2/25 (8%)	11/83 (13%)
<i>IDH2R140</i>	6/25 (24%)	17/83 (20%)

NC: Not Communicated